1-(PERFLUOROHEXYL)OCTANE

Absorption

Perfluorohexyloctane penetrates meibomian glands, where it has been reported to interact with and dissolve the altered, viscous meibum in the glands. A single pharmacokinetic study showed low systemic perfluorohexyloctane blood levels after topical ocular administration. In rabbits, perfluorohexyloctane was detected in tears at six hours and in meibomian glands at 24 hours following ophthalmic administration, with minimal systemic exposure.

Toxicity

There is limited information regarding acute toxicity (LD50) or overdosage of perfluorohexyloctane.

The Uses of 1-(PERFLUOROHEXYL)OCTANE

1-(Perfluorohexyl)octane is used in preparation of Fluoroalkane by reduction of Halofluoroalkane in presence of precious metal catalyst and inorganic compound.

Background

Perfluorohexyloctane is a semifluorinated alkane that contains six perfluorinated carbon atoms and eight hydrogenated carbon atoms. It is an inert, slightly amphiphilic compound. Because it is a completely non-aqueous liquid, microbial growth is not possible; therefore, its drug products do not need to be combined with any preservative.
Perfluorohexyloctane has been used in the field of ophthalmology as a vitreous substitute. It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.

Indications

Perfluorohexyloctane ophthalmic formulation is indicated for the treatment of the signs and symptoms of dry eye disease.

Flammability and Explosibility

Non flammable

Pharmacokinetics

Perfluorohexyloctane is administered ophthalmically to alleviate symptoms of dry eye disease, increase tear film breakup time, and increase lipid layer thickness. Having low surface and interface tensions, perfluorohexyloctane spreads rapidly across the ocular surface. It is reported to cause minimal visual disturbances, attributed to its refractive index being similar to that of water.

Metabolism

Perfluorohexyloctane was not metabolized by human liver microsomes in vitro.